<DOC>
	<DOCNO>NCT02318329</DOCNO>
	<brief_summary>This three-part , open-label , safety , tolerability , PK study FPA144 . Patients enrol Part 1 ( A B , dose escalation ) Part 2 ( dose expansion ) study , .</brief_summary>
	<brief_title>Open-Label , Dose-Finding Study Evaluating Safety PK FPA144 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Part 1A dose-escalation study patient locally advance metastatic solid tumor lymphoma standard therapy exhaust . Part 1B assess safety evaluate PK FPA144 gastric cancer patient . Part 2 patient enrol treated order characterize safety preliminary efficacy select cancer patient population great potential clinical benefit FPA144 treatment .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Life expectancy least 3 month ECOG performance status 0 1 Adequate hematological organ function , confirm lab value Tumor tissue determination FGFR2b overexpression FGFR2 amplification ( optional Part 1A patient ) QTc segment &gt; 470 msec Treatment anticancer therapy investigational drug &lt; /=14 day ( &lt; /=28 day patient Korea ) prior first dose FPA144 Presence condition may increase risk associate study participation interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FGFR2b , FGFR2 , FGFR , bladder neoplasm , esophageal cancer</keyword>
</DOC>